箭头在Science of HBV Cure 2019

newchinabok

http://ir.arrowheadpharma.com/events-and-presentations

newchinabok

Science of HBV Cure 2019
Supporting Materials:
View Presentation
Location:
Singapore
View Additional Information

天上飞鱼

箭头专家表示：1、打了3针效果不错，计划延长打针时间，并开始联合用药试验，看看试验结果如何。2、认为将表抗降低到100以下后，自发转阴的概率大大提高，加入免疫刺激药物没啥用。试验显示，患者对aro-hbv和520的反应相似，根据520的患者随访结果，有患者在随访26月后表面抗原转阴了。所以就慢慢等好了

fuke

回复 天上飞鱼 的帖子

即使低于100可以自然转阴，但是概率也太低了。如果他的效果仅仅是降低表抗到100，然后等自然转阴，估计这个肯定是不行

齐欢畅

Some Informed Speculation (My Opinion Only)
• Finite therapy with Interferon and now NUCs has been associated with HBsAg
seroclearance rates beyond spontaneous background
• Often after a few years
• ARC-520 data even with background NUCs continuing looks similar to my eye
• JNJ-3989, representing the current generation of RNAi agents, can reduce all viral
components and importantly might get HBsAg in most patients below 100 IU/ml
• True finite therapy, including stopping background NUCs, will be fascinating to watch in
the next few years
• Adding immune stimulation at this point only adds to the anticipation

齐欢畅

RNAi: Pulling Us Toward Finite Therapy
The Science of HBV Cure 2019
Singapore, June 7-8, 2019
Bruce D. Given, MD
COO, Arrowhead Pharmaceuticals

newchinabok

，排列组合

齐欢畅

干扰素+taf+arohbv已经可以解决很多人的问题了。